• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Alumis Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    6/30/25 4:19:18 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    0001847367false00018473672025-05-212025-05-21

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K/A
    (Amendment No. 1)

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 21, 2025

    Alumis Inc.

    (Exact name of Registrant as Specified in Its Charter)

    ​

    Delaware

        

    001-42143

        

    86-1771129

    (State or Other Jurisdiction
    of Incorporation)

     

    (Commission
    File Number)

     

    (IRS Employer
    Identification No.)

    ​

    280 East Grand Avenue

    South San Francisco, California 94080

    (Address of Principal Executive Offices)

    Registrant’s Telephone Number, Including Area Code: (650) 231-6625

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading
    Symbol(s)

        

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share

     

    ALMS

     

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

    ​

    ​

    Explanatory Note

    As previously reported, on May 21, 2025, Alumis Inc., a Delaware corporation (the “Company”), completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of February 6, 2025, as amended on April 20, 2025 (the “Merger Agreement”), by and among the Company, Arrow Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of the Company (“Merger Sub”), and ACELYRIN, Inc. (“ACELYRIN”), pursuant to which Merger Sub merged with and into ACELYRIN, with ACELYRIN continuing as the surviving corporation and as a wholly owned subsidiary of the Company. This Amendment No. 1 on Form 8-K/A is being filed by the Company to amend the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 21, 2025 (the “Original Report”), solely to provide the disclosures required by Item 9.01 of Form 8-K that were not previously filed with the Original Report.

    ​

    Item 9.01 Financial Statements and Exhibits.

    (a) Financial Statements of Business Acquired

    The financial statements and information required by this Item 9.01(a) and the notes related thereto are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K.

    (b) Pro Forma Financial Information

    The pro forma financial information required by this Item 9.01(b) and the notes related thereto are filed as Exhibit 99.3 to this Current Report on Form 8-K.

    (d) Exhibits

    Exhibit
    No.

        

    Description

    ​

    ​

    ​

    2.1+

    ​

    Agreement and Plan of Merger, dated February 6, 2025, by and among Alumis Inc., ACELYRIN, Inc. and Arrow Merger Sub, Inc. (incorporated herein by reference to Exhibit 2.1 of Alumis Inc.’s Current Report on Form 8-K filed with the SEC on February 6, 2025).

    ​

    ​

    ​

    2.2

    ​

    Amendment to the Agreement and Plan of Merger, dated as of April 20, 2025, by and among Alumis Inc., ACELYRIN, Inc. and Arrow Merger Sub, Inc. (incorporated herein by reference to Exhibit 2.1 to Alumis Inc.’s Current Report on Form 8-K filed with the SEC on April 21, 2025).

    ​

    ​

    ​

    23.1*

    ​

    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of ACELYRIN, Inc.

    ​

    ​

    ​

    99.1*

    ​

    Audited financial statements of ACELYRIN, Inc. as of and for the years ended December 31, 2024 and 2023.

    ​

    ​

    ​

    99.2*

    ​

    Unaudited financial statements of ACELYRIN, Inc. as of and for the three months ended March 31, 2025.

    ​

    ​

    ​

    99.3*

    ​

    Unaudited pro forma condensed combined financial information.

    ​

    ​

    ​

    104*

      

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    *

    Filed herewith.

    +

    Certain exhibits and schedules to the Agreement and Plan of Merger have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Alumis Inc. will furnish copies of such exhibits and schedules to the SEC upon its request.

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    Alumis Inc.

    ​

    ​

    Dated: June 30, 2025

    By:

    /s/ Martin Babler

    ​

    Name:

    Martin Babler

    ​

    Title:

    President & Chief Executive Officer

    ​

    ​

    Get the next $ALMS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    7/25/2025$17.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy
    Guggenheim
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    7/23/2024Overweight
    Cantor Fitzgerald
    7/23/2024$29.00Outperform
    Leerink Partners
    7/23/2024$32.00Buy
    Guggenheim
    More analyst ratings

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Yao Zhengbin

    4 - ALUMIS INC. (0001847367) (Issuer)

    8/1/25 4:05:11 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Machado Patrick

    4 - ALUMIS INC. (0001847367) (Issuer)

    8/1/25 4:05:08 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Tetrault Lynn A.

    4 - ALUMIS INC. (0001847367) (Issuer)

    8/1/25 4:05:13 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tananbaum James B. bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    5/6/25 9:48:59 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Labs, Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    5/6/25 9:48:12 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Capital Management Vi Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    5/6/25 9:47:18 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Alumis with a new price target

    Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00

    7/25/25 9:06:03 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim resumed coverage on Alumis with a new price target

    Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00

    6/10/25 8:07:01 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Alumis with a new price target

    Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

    1/30/25 7:47:22 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    –Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in Q3 2026– –Completed merger with ACELYRIN, Inc. to strengthen financial position and support advancement of late-stage immunology pipeline– –Cash, cash equivalents and marketable securities of $486.3 million as of June 30, 2025 expected to fund operations into 2027– SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical comp

    8/13/25 4:05:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

    -Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of systemic lupus erythematosus (SLE), the most common form of lupus. "Completion of enrollment in our global LUMUS Phase 2b trial for SLE marks a significant milestone for Alumis, and importantly, for the lupus community," said Martin Babler, Presiden

    7/24/25 7:30:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

    SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary. Sanam most recently served as Senior Vice President, Legal of Alumis. In her new role, she will lead all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory on key decisions and transactions. Sanam succeeds Sara Klein, following her retirement from the company. "We're thrilled to elevate Sanam to the role of Chief Legal Officer," s

    7/14/25 4:05:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    SEC Filings

    View All

    SEC Form EFFECT filed by Alumis Inc.

    EFFECT - ALUMIS INC. (0001847367) (Filer)

    8/20/25 12:15:10 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alumis Inc.

    10-Q - ALUMIS INC. (0001847367) (Filer)

    8/13/25 4:57:26 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALUMIS INC. (0001847367) (Filer)

    8/13/25 4:14:52 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Financials

    Live finance-specific insights

    View All

    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

    2/6/25 4:15:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    8/27/24 4:20:38 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alumis Inc.

    SC 13G - ALUMIS INC. (0001847367) (Subject)

    7/11/24 4:30:21 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    7/5/24 9:30:17 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care